With a commitment to improving the prognosis of heart valve diseases, Aptus Bioreactors provides novel bioreactor systems and accessories capable of creating and testing living, patient-specific, tissue engineered heart valves (TEHVs). Using the TEHVs, we envision “One Surgery, for Life” where hospital costs, risks, and other burdens associated with heart valve disease are eliminated.
Please join us in making this a reality!
Featured Technology
Featured Blog Posts
In the recent weeks, Aptus Bioreactors has decided to partner with a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, New Hampshire, ARMI is the 12th Manufacturing USA Institute. ARMI brings together a consortium of over 100 partner organizations from industry, government, academia and the non-profit sector to develop the next-generation manufacturing processes and technologies for cells, tissues and organs.
After much time, we are happy to announce the launch of our Rotating Cell Seeder (RC Seeder). This technology can be used in the development of novel tissue engineered heart valves by allowing location-specific cell seeding to heart valve roots. The device provides control over rotation style and speed, is autoclavable for repeated use, and provides gas exchange in a sterile in vitro environment.
The researchers at Qatar University used Aptus Bioreactors’ Pulse Duplicator System (Heart Valve Bioreactor) to test and validate the performance of their engineered heart valves compared to commercially available valves.